Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%.

Research presented by Professor Cecilia Johansson of Imperial College London has linked early type I interferon signalling in ...

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development ...

In a study published in The Journal of Clinical Investigation, University of Michigan researchers found a new protein target ...

When you're pounding along an icy pavement or sweating through a gym workout, you try to remind yourself of the many health benefits of exercise. Between gasps, you can say that a healthy, fit ...

Patients with a lung neoplasm, NSCLC histology, and treatment information in their notes were selected from a repository of over 27 million patients. From these, 200 were randomly selected for this ...

Small cell lung cancer (SCLC) is one of the most dangerous forms of lung cancer. It grows and spreads very quickly. Sadly, ...

Researchers at the University of Cologne discovered a new mechanism used by one of the most aggressive forms of lung cancer to escape treatment, paving the way for more efficient future therapies / ...